-
Jasplakinolide in Actin Cytoskeleton Research
2026-10-05
Jasplakinolide is a marine-derived compound used as an actin polymerization inducer and cytoskeletal research probe. This overview separates supplier-reported properties from findings in the supplied peer-reviewed literature, explains how Jasplakinolide can frame questions about filament organization and cell behavior, and compares the evidentiary value of direct actin studies with the indirectly relevant chemical-genetics work of Zheng et al. The available material supports conceptual use in cell biology research, but it is insufficient for broad claims about therapeutic translation, antifungal performance, or disease relevance.
-
CA2 Perineuronal Nets and Social Memory in Alzheimer’s
2026-10-04
A 2025 mouse study links hippocampal CA2 perineuronal-net disruption with social memory impairment in Alzheimer’s disease. The findings support a mechanistic hypothesis involving matrix metalloproteinases, while remaining preliminary because they rely on the 5XFAD model and do not establish human therapeutic efficacy.
-
Cell Cycle Assay Kit in CRC Research: Evidence and Limits
2026-10-03
A source-grounded overview of how DNA-content flow cytometry can contextualize colorectal cancer research, including the reported effects of Cya-Gly-Fer, interpretive value, evidence strength, and key limitations.
-
RUNX2 Epigenetic Repression and ICB Resistance in OS
2026-10-02
This study identifies a RUNX2–NCOR1–HDAC3 repressor complex that suppresses cGAS–STING–IFN-I signaling in osteosarcoma, reducing tumor sensitivity to immune checkpoint blockade. Its preclinical data support combining HDAC3 inhibition with anti-PD-1 therapy to restore interferon activity while counteracting the accompanying induction of PD-L1 and PD-L2.
-
Anagliptin: An Assay-First Guide to Vascular Biology
2026-10-01
Anagliptin (SK-0403) is a potent DPP-4 inhibitor and a useful probe for connecting incretin biology with vascular smooth-muscle pharmacology. This assay-first guide explains how Kv channel modulation and SERCA pump regulation can be tested without overinterpreting ex vivo findings.
-
From Tau Ser356 Biology to Translational Screening
2026-10-01
A translational framework for interpreting tau Ser356 biology, using NUAK inhibition as a mechanistic benchmark, and positioning Linagliptin (BI-1356) as an adjacent metabolic research comparator without overstating evidence.
-
DiR Imaging for Trypsin-Responsive Nanomedicine
2026-09-30
DiR (DiIC 18 (7)) can add a critical imaging layer to trypsin-responsive nanomedicine for acute pancreatitis: mapping membrane-associated delivery, biodistribution, and retention while separating what fluorescence demonstrates from what requires orthogonal validation.
-
Linagliptin (BI-1356) and Tau Ser356 Research
2026-09-30
Linagliptin (BI-1356) is a DPP-4 inhibitor, not a NUAK inhibitor. This article explains how to evaluate it as an orthogonal pharmacological probe in tau Ser356 studies without confusing disease association with mechanism.
-
Vancomycin in Reliable Cell Assays
2026-09-29
Learn how Vancomycin SKU C6417 can help laboratories distinguish bacterial contamination from genuine cell toxicity while improving antimicrobial-control workflows. The article covers mechanism, solvent compatibility, assay controls, data interpretation, and evidence-based product selection.
-
QX77 Molecular Chaperone Activator Workflows
2026-09-29
QX77 is a molecular chaperone activator for dissecting LAMP2A- and Rab11-linked trafficking, with added utility in ES cell self-renewal and differentiation assays. This workflow emphasizes flux-aware controls, dose and time optimization, and careful separation of CMA biology from mitochondrial mitophagy mechanisms.
-
Immobilized Microalgae for Antioxidant Active Packaging
2026-09-28
This study used a silk fibroin–reinforced alginate gel to immobilize Chlorella sp., increasing biomass and polysaccharide yield relative to suspension culture. The resulting extract showed heat-tolerant radical-scavenging activity and improved the antioxidant and moisture-barrier performance of biodegradable films in an apple-slice preservation test.
-
Anagliptin (SK-0403): DPP-4 and Vascular Evidence
2026-09-27
Anagliptin (SK-0403) is an orally active DPP-4 inhibitor used in diabetes and metabolic research. In rabbit aortic rings, a 2025 study found vasorelaxation associated with Kv-channel activity and SERCA-pump function, while leaving important limits on translation to other models.
-
IBAT Inhibition as a Translational Strategy
2026-09-26
Elobixibat hydrate offers a way to probe how intestinal bile-acid handling connects gut function with metabolic readouts. This article lays out the mechanism, evidence boundaries, and practical choices that can strengthen translational study design.
-
Tau pSer356 and NUAK Inhibition in Alzheimer’s Disease
2026-09-26
Taylor et al. report that tau phosphorylated at serine 356 (p-tau Ser356) increases with Alzheimer’s disease neuropathological stage and is found in most neurofibrillary tangles examined. Their comparison of mouse and human brain-slice cultures also reveals an important model-dependent response to the NUAK1/2 inhibitor WZ4003: p-tau Ser356 falls in both systems, but broader protein changes differ.
-
Oligo (dT) 25 Beads: Practical mRNA Workflow
2026-09-25
Oligo (dT) 25 Beads provide a magnetic route to enrich polyadenylated eukaryotic mRNA from total RNA or prepared animal and plant samples. They are suited to polyA-bearing transcript workflows, including RT-PCR and first-strand cDNA synthesis, but not to isolating non-polyadenylated RNA or replacing sample lysis and RNA quality control.